BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11707648)

  • 1. Synthetic 1,4-anthracenediones, which block nucleoside transport and induce DNA fragmentation, retain their cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
    Wu M; Wang B; Perchellet EM; Sperfslage BJ; Stephany HA; Hua DH; Perchellet JP
    Anticancer Drugs; 2001 Nov; 12(10):807-19. PubMed ID: 11707648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
    Wang B; Wu M; Perchellet EM; McIlvain CJ; Sperfslage BJ; Huang X; Tamura M; Stephany HA; Hua DH; Perchellet JP
    Int J Oncol; 2001 Dec; 19(6):1169-78. PubMed ID: 11713586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Among substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetraones, the lead antitumor triptycene bisquinone TT24 blocks nucleoside transport, induces apoptotic DNA fragmentation and decreases the viability of L1210 leukemic cells in the nanomolar range of daunorubicin in vitro.
    Perchellet EM; Sperfslage BJ; Wang Y; Huang X; Tamura M; Hua DH; Perchellet JP
    Anticancer Drugs; 2002 Jul; 13(6):567-81. PubMed ID: 12172502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.
    Perchellet EM; Magill MJ; Huang X; Dalke DM; Hua DH; Perchellet JP
    Anticancer Drugs; 2000 Jun; 11(5):339-52. PubMed ID: 10912950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of poly(ADP-ribose) polymerase-1 cleavage by antitumor triptycene bisquinones in wild-type and daunorubicin-resistant HL-60 cell lines.
    Wang Y; Perchellet EM; Tamura M; Hua DH; Perchellet JP
    Cancer Lett; 2002 Dec; 188(1-2):73-83. PubMed ID: 12406551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor triptycene bisquinones induce a caspase-independent release of mitochondrial cytochrome c and a caspase-2-mediated activation of initiator caspase-8 and -9 in HL-60 cells by a mechanism which does not involve Fas signaling.
    Perchellet EM; Wang Y; Weber RL; Lou K; Hua DH; Perchellet JP
    Anticancer Drugs; 2004 Nov; 15(10):929-46. PubMed ID: 15514562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptycenes: a novel synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, induce DNA cleavage and decrease the viability of leukemic cells in the nanomolar range in vitro.
    Perchellet EM; Magill MJ; Huang X; Brantis CE; Hua DH; Perchellet JP
    Anticancer Drugs; 1999 Sep; 10(8):749-66. PubMed ID: 10573208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic 1,4-anthracenedione analogs induce cytochrome c release, caspase-9, -3, and -8 activities, poly(ADP-ribose) polymerase-1 cleavage and internucleosomal DNA fragmentation in HL-60 cells by a mechanism which involves caspase-2 activation but not Fas signaling.
    Perchellet EM; Wang Y; Weber RL; Sperfslage BJ; Lou K; Crossland J; Hua DH; Perchellet JP
    Biochem Pharmacol; 2004 Feb; 67(3):523-37. PubMed ID: 15037204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinone isomers of the WS-5995 antibiotics: synthetic antitumor agents that inhibit macromolecule synthesis, block nucleoside transport, induce DNA fragmentation, and decrease the growth and viability of L1210 leukemic cells more effectively than ellagic acid and genistein in vitro.
    Perchellet EM; Sperfslage BJ; Qabaja G; Jones GB; Perchellet JP
    Anticancer Drugs; 2001 Jun; 12(5):401-17. PubMed ID: 11395569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
    Toffoli G; Simone F; Gigante M; Boiocchi M
    Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria treated with anti-tumor 1,4-anthracenediones.
    Wang Y; Perchellet EM; Ward MM; Lou K; Hua DH; Perchellet JP
    Anticancer Drugs; 2005 Oct; 16(9):953-67. PubMed ID: 16162972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
    Jiang XR; Kelsey SM; Wu YL; Newland AC
    Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells.
    Côme MG; Skladanowski A; Larsen AK; Laurent G
    Br J Cancer; 1999 Mar; 79(7-8):1090-7. PubMed ID: 10098741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance.
    Andrivon W; Monneret C; Nafziger J; Florent JC; Guillosson JJ
    Leuk Res; 1998 Aug; 22(8):719-25. PubMed ID: 9680099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines.
    Toffoli G; Corona G; Simone F; Gigante M; De Angeli S; Boiocchi M
    Int J Cancer; 1996 Jul; 67(1):129-37. PubMed ID: 8690513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antileukemic activity of synthetic daunomycinone derivatives bearing modifications in the glycosidic moiety.
    Perchellet EM; Sperfslage BJ; McIlvain CJ; Aligiannis N; Pouli N; Marakos P; Skaltsounis AL; Perchellet JP
    Anticancer Res; 2001; 21(6A):3957-67. PubMed ID: 11911277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer.
    Alakhov VYu ; Moskaleva EYu ; Batrakova EV; Kabanov AV
    Bioconjug Chem; 1996; 7(2):209-16. PubMed ID: 8983343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
    Choi CH; Ling V
    Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
    Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
    Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.